Business Description
Humacyte Inc
NAICS : 325412
SIC : 2834
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Description
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.04 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | -73.82 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 92.04 | |||||
| 9-Day RSI | 82.94 | |||||
| 14-Day RSI | 71.95 | |||||
| 6-1 Month Momentum % | -38.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.45 | |||||
| Quick Ratio | 19.45 | |||||
| Cash Ratio | 19.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -8.75 | |||||
| ROA % | -3.09 | |||||
| ROIC % | -99.5 | |||||
| ROC (Joel Greenblatt) % | -8.36 | |||||
| ROCE % | -1.77 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.37 | |||||
| Price-to-Tangible-Book | 4.36 | |||||
| EV-to-EBIT | -64.21 | |||||
| EV-to-EBITDA | -443.26 | |||||
| EV-to-Forward-Revenue | 142.6 | |||||
| EV-to-FCF | -5.07 | |||||
| Price-to-Net-Current-Asset-Value | 9.36 | |||||
| Price-to-Net-Cash | 10 | |||||
| Earnings Yield (Greenblatt) % | -1.56 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:HUMA
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -0.5 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 71.95 | ||
| 14-Day ATR ($) | 0.270085 | ||
| 20-Day SMA ($) | 3.50625 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 3.07 - 17.45 | ||
| Shares Outstanding (Mil) | 103 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Humacyte Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||